发现了harmiprims,harmine-primaquine杂交物,作为强效和选择性的抗癌和抗疟疾化合物
Kristina Pavić1, Goran Poje1, Lais Pessanha de Carvalho2
1University of Zagreb Faculty of Pharmacy and Biochemistry, A. Kovačića 1, 10000 Zagreb, Croatia.
Bioorganic & medicinal chemistry
|April 27, 2024
概括
新的harmiprims,抗癌harmine和抗疟疾primaquine的混合物,对癌细胞和疟疾寄生虫表现出强大的活性. 迪梅里克harmiprime表现出广泛的抗血性活性,而其他杂交物则显示出选择性的抗癌作用.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 寄生虫学的寄生虫学
背景情况:
- 现有的抗癌和抗疟疾药物因耐药性增加而面临挑战.
- 在癌症和疟疾之间重新定位药物是由于共享机制而已知的策略.
- 迫切需要新型化学型来扩大两种疾病的药物组合.
研究的目的:
- 设计和合成结合harmine和primaquine的新型混合化合物 (harmiprims).
- 评估这些新化学实体的抗增殖和抗质活动.
- 研究合成的harmiprims的作用机制和细胞局部化.
主要方法:
- 通过三醇或尿素部分连接的harmine-primaquine杂交物 (harmiprims) 的合成.
- 在实验室中对抗癌细胞系 (例如,MCF-7) 的抗增殖活性进行评估.
- 在Plasmodium生命周期各个阶段对抗原菌活性进行体外查.
- 用于DNA结合评估的光谱光度和热变性研究.
- 细胞局部化,细胞周期分析和计算对接研究.
主要成果:
- 哈米普林斯表现出不同的抗增殖活性;C1替代的尿素混合体对测试的细胞系最有效.
- 取代N-9的三醇harmiprime显示对MCF-7细胞具有选择性.
- 狄米瑞克harmiprime表现出强烈的,无毒的,三级抗血活性,与PfHsp90.0结合.
- 哈米普林与dS-DNA槽结合,但不会进入细胞核或线粒体.
- 在癌细胞中诱导G1细胞循环停止的C1替代的尿素混合体.
结论:
- 哈米普林斯是一种有前途的混合分子类,具有双重抗癌和抗等离子体潜力.
- 迪米瑞克harmiprime是进一步开发作为广泛的抗疟疾药物的强有力的候选者.
- 抗增殖效应不是通过核或线粒体内的直接DNA相互作用来介导的.
相关概念视频
Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


